Wuhan Pharmx Pharmaceutical

Pharmx Pharmaceutical is a clinical-stage biopharmaceutical company based in Wuhan, China, specializing in the discovery and development of innovative small molecule therapies for metabolic and endocrine diseases. The company's primary focus is on multi-agonist treatments for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Their lead programs include oral and injectable GLP-1, GIP, and Glucagon receptor agonists designed to provide superior efficacy and safety profiles compared to existing treatments. Pharmx leverages its expertise in medicinal chemistry to develop next-generation metabolic regulators that address the growing global burden of cardiometabolic disorders.